Skip to content

Study · Animal study (in vivo) · rat · 2015

5 results

Decreased consumption of rewarding sucrose solutions after injection of melanocortins into the ventral tegmental area of rats.

Yen HH, Roseberry AG

Psychopharmacology3 Jul 2014Cited by 30 (Europe PMC)

PMID24985892 (opens in a new tab)DOI10.1007/s00213-014-3663-6 (opens in a new tab)PepBankPUB-24985892
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII injected into the ventral tegmental area dose-dependently decreased intake of 1 and 2 % sucrose solutions.

    In plain wordsIn rats, MTII injected into a brain reward area reduced drinking of weak sugar solutions as the dose rose.

    Peptide
    Melanotan II
    Outcome
    DecreaseIntake of 1 and 2 % sucrose solutions
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intra-VTAAs given in this study (rat).

    Source sentences

    Summary
    Injection of MTII into the VTA dose dependently decreased the intake of 1 and 2 % sucrose solutions
    1 context sentence
    Summary · context
    Varying doses of the melanocortin receptor agonist, MTII, were injected into the VTA, and the intake of different sugar solutions was measured in two-bottle choice tests to distinguish between potential effects on homeostatic versus hedonic aspects of feeding.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII injected into the ventral tegmental area dose-dependently decreased intake of 0.2 % saccharin solution.

    In plain wordsIn rats, MTII injected into a brain reward area reduced drinking of a saccharin solution as the dose rose.

    Peptide
    Melanotan II
    Outcome
    DecreaseIntake of 0.2 % saccharin solution
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intra-VTAAs given in this study (rat).

    Source sentences

    Summary
    Injection of MTII into the VTA dose dependently decreased the intake of 1 and 2 % sucrose solutions and 0.2 % saccharin solutions
    1 context sentence
    Summary · context
    Varying doses of the melanocortin receptor agonist, MTII, were injected into the VTA, and the intake of different sugar solutions was measured in two-bottle choice tests to distinguish between potential effects on homeostatic versus hedonic aspects of feeding.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII injected into the ventral tegmental area decreased 24-h food intake in each study.

    In plain wordsIn rats, MTII injected into a brain reward area reduced food eaten over 24 hours.

    Peptide
    Melanotan II
    Outcome
    Decrease24-h food intake
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intra-VTAAs given in this study (rat).

    Source sentences

    Summary
    and decreased 24-h food intake in each study.
    1 context sentence
    Summary · context
    Varying doses of the melanocortin receptor agonist, MTII, were injected into the VTA, and the intake of different sugar solutions was measured in two-bottle choice tests to distinguish between potential effects on homeostatic versus hedonic aspects of feeding.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to 10 % sucrose, only the highest MTII dose into the ventral tegmental area reduced sucrose intake.

    In plain wordsIn rats given strong sugar solution, only the highest MTII dose reduced sugar intake.

    Peptide
    Melanotan II
    Outcome
    DecreaseIntake of 10 % sucrose solution
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intra-VTAAs given in this study (rat).

    Source sentences

    Summary
    Although MTII also decreased the intake of a 10 % sucrose solution, MTII appeared to be less potent in rats exposed to 10 % sucrose, as only the highest dose of MTII tested was effective at reducing 10 % sucrose intake and food intake in these rats.
    1 context sentence
    Summary · context
    Varying doses of the melanocortin receptor agonist, MTII, were injected into the VTA, and the intake of different sugar solutions was measured in two-bottle choice tests to distinguish between potential effects on homeostatic versus hedonic aspects of feeding.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to 10 % sucrose, only the highest MTII dose into the ventral tegmental area reduced food intake.

    In plain wordsIn rats given strong sugar solution, only the highest MTII dose reduced food intake.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood intake in rats exposed to 10 % sucrose
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intra-VTAAs given in this study (rat).

    Source sentences

    Summary
    Although MTII also decreased the intake of a 10 % sucrose solution, MTII appeared to be less potent in rats exposed to 10 % sucrose, as only the highest dose of MTII tested was effective at reducing 10 % sucrose intake and food intake in these rats.
    1 context sentence
    Summary · context
    Varying doses of the melanocortin receptor agonist, MTII, were injected into the VTA, and the intake of different sugar solutions was measured in two-bottle choice tests to distinguish between potential effects on homeostatic versus hedonic aspects of feeding.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.